VOR

19.1703.51%
JK

Jean-Paul Kress

Chairman, President & CEO

Dr. Jean-Paul Kress, M.D., is Chairman, President & Chief Executive Officer of Vor Biopharma Inc. from June 25, 2025. Dr. Kress is Independent Director of Sanofi from January 1, 2025. Dr. Kress had been the Chief Executive Officer of MorphoSys AG since September 1, 2019 until 2024 and had been its Management Board Member since 2019 until 2024 and served as its Chairman of Management Board until 2024. Dr. Kress was the President and Chief Executive Officer of Syntimmune, Inc from January 2018 until its acquisition by Alexion Pharmaceuticals in November 2018. Dr. Kress served as an Executive Vice President, President of International and Head of Global Therapeutic Operations at Biogen Inc. since June 19, 2017 until January 2018. Dr. Kress had direct responsibility for worldwide commercial operations outside the U.S. and also oversaw the Rare and Specialty Disease Asset teams. Previously, Dr. Kress served as Senior Vice President, Head of North America, Sanofi Genzyme Specialty Care Business Unit (Multiple Sclerosis, Oncology & Immunology) since September 2015 until June 2017. Dr. Kress worked at Abbvie and Eli Lilly in senior commercial and business development roles in the United States and in Europe. Dr. Kress served as President of Sanofi Pasteur MSD ApS. He served as President of Sanofi Pasteur MSD Limited from July 2011 to September 2015 and also served as its Chief Executive Officer until 2015. During his tenure with Sanofi Pasteur MSD, a joint venture between Sanofi Pasteur and Merck & Co (known as MSD outside the US and Canada), he embarked on a series of changes to reshape MSD to better meet the challenges of the rapidly changing vaccine industry and to drive the launches of a number of innovative new products. His ability to mobilize MSD to focus on the most critical priorities resulted in a turnaround of the business and provided a firm foundation for sustainable growth. A strong advocate for the socio-economic value of vaccination, Dr. Kress was actively involved in the development of health policy across the EU with a focus on disease prevention. Prior to his work at Sanofi Pasteur MSD, he served as Vice President and General Manager in France for Gilead, a major US-based biopharmaceutical company specialized in therapeutics for life-threatening diseases such as HIV. He joined Gilead in California in 2006 as Vice President, US Sales and Marketing. He served as a Director of Sarepta Therapeutics, Inc. from September 30, 2015 to June 6, 2017. He had been the Chairman of the Board at PHAXIAM Therapeutics S.A. (formerly known as ERYTECH Pharma S.A.) since June 21, 2019. He has been a Director of Syntimmune, Inc. since June 1, 2018. He serves as a Director of CNE (the ENS Alumni association). Dr. Kress holds an M.D. degree from Faculté Necker-Enfants Malades in Paris and graduate and Master of Sciences in molecular and cellular pharmacology and biochemistry from École Normale Supérieure in Paris.

Positions